Immunovant (NASDAQ:IMVT) Director Atul Pande Sells 6,000 Shares of Stock

Posted by Stanley Muller on May 21st, 2026

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) Director Atul Pande sold 6,000 shares of the stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $32.00, for a total value of $192,000.00. Following the completion of the sale, the director owned 116,731 shares in the company, valued at approximately $3,735,392. The trade was a 4.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Immunovant Trading Up 35.3%

Shares of NASDAQ IMVT opened at $35.56 on Thursday. The stock has a market cap of $7.24 billion, a P/E ratio of -13.22 and a beta of 0.70. Immunovant, Inc. has a 12-month low of $13.79 and a 12-month high of $36.29. The business’s fifty day simple moving average is $26.48 and its 200-day simple moving average is $25.78.

Immunovant (NASDAQ:IMVT – Get Free Report) last announced its quarterly earnings data on Wednesday, May 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.13). During the same quarter last year, the business posted ($0.64) earnings per share. On average, equities analysts forecast that Immunovant, Inc. will post -2.67 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on IMVT. Guggenheim increased their price objective on Immunovant from $41.00 to $44.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Bank of America reissued a “buy” rating on shares of Immunovant in a report on Thursday. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Immunovant in a report on Tuesday, February 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunovant in a report on Wednesday, April 8th. Finally, The Goldman Sachs Group increased their target price on Immunovant from $29.00 to $32.00 and gave the company a “neutral” rating in a report on Wednesday, April 15th. Six research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $32.44.

Check Out Our Latest Analysis on Immunovant

Hedge Funds Weigh In On Immunovant

Several large investors have recently bought and sold shares of IMVT. RTW Investments LP purchased a new position in Immunovant in the fourth quarter valued at $80,781,000. Morgan Stanley increased its holdings in Immunovant by 147.4% in the fourth quarter. Morgan Stanley now owns 4,846,385 shares of the company’s stock valued at $123,195,000 after buying an additional 2,887,359 shares during the last quarter. Jennison Associates LLC grew its holdings in shares of Immunovant by 356.4% during the first quarter. Jennison Associates LLC now owns 3,196,705 shares of the company’s stock worth $79,406,000 after purchasing an additional 2,496,241 shares during the last quarter. ADAR1 Capital Management LLC grew its holdings in shares of Immunovant by 319.0% during the third quarter. ADAR1 Capital Management LLC now owns 2,241,753 shares of the company’s stock worth $36,137,000 after purchasing an additional 1,706,687 shares during the last quarter. Finally, Logos Global Management LP grew its holdings in shares of Immunovant by 400.0% during the fourth quarter. Logos Global Management LP now owns 1,375,000 shares of the company’s stock worth $34,952,000 after purchasing an additional 1,100,000 shares during the last quarter. Hedge funds and other institutional investors own 47.08% of the company’s stock.

Immunovant News Summary

Here are the key news stories impacting Immunovant this week:

Positive Sentiment: Immunovant reported strong Week 16 results from its rheumatoid arthritis study of IMVT-1402, with encouraging response rates that investors viewed as clinically meaningful and supportive of the drug’s potential. Article Title
Positive Sentiment: The company said its cutaneous lupus proof-of-concept trial is fully enrolled and expects topline data in the second half of 2026, giving investors another near-term catalyst. Article Title
Positive Sentiment: Immunovant also highlighted a cash position of about $902 million as of March 31, which should help fund development and support the path toward a possible commercial launch of IMVT-1402 in Graves’ disease. Article Title
Neutral Sentiment: Quarterly results were weaker than expected, with a loss of $0.73 per share versus the $0.60 estimate, but the earnings miss was largely overshadowed by the clinical update. Article Title
Negative Sentiment: Director Atul Pande sold 6,000 shares in a pre-arranged transaction, which may slightly temper sentiment even though it was disclosed under a Rule 10b5-1 plan. Article Title

About Immunovant

(Get Free Report)

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.